FIGURE 1.

Myricetin inhibits TGEV infection and affects viral growth in PK-15 cells. (A) Cell viability of PK-15 cells treated with various concentrations of myricetin (0–1000 μM) for 48 h. (B) PK-15 cells were infected with TGEV and treated with different concentrations of myricetin for 24 h. The inhibition rate of TGEV infection was calculated by comparing the percentage of cell viability in treated cells to that of untreated cells. Results showed that myricetin inhibited TGEV infection in a dose-dependent manner. (C) Effects of different concentrations of myricetin on TGEV growth curve. Real-time fluorescence quantification assays were performed to observe the TGEV N gene copies. The y-axis represents the copies, and the x-axis indicates myricetin treatment time. (D–I) Copies of the TGEV N gene were measured at 4, 8, 12, 24, 36, and 48 h after infection. The terms “Mock”, “25 μM”, “50 μM”, and “100 μM” refer to different treatments with myricetin at different concentrations, including no treatment (0 μM), 25, 50, and 100 μM, respectively. Data are presented as mean ± SD of three independent experiments. The different symbols on the columns represent the significant differences compared with mock group (*P < 0.05; **P < 0.01; ***P < 0.001).